ArticleGland surgery2022
Analysis of the accuracy of ultrasound elastography and BI-RADS classification of breast masses located within the superficial fat layer of the glands.
Article in Gland surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 4 citations in OpenAlex.
- The role of combined ultrasonic BI-RADS and ultrasound elastography in discriminating between benign and malignant breast nodules.Medicine · 2026Article
- Stratifying Breast Lesion Risk Using BI-RADS: A Correlative Study of Imaging and Histopathology.Medicina (Kaunas, Lithuania) · 2025Article
- Pilomatricoma of the breast similar to breast cancer on ultrasound and elastography: a case report.AME case reports · 2025Article
- Diagnostic efficacy of ultrasound elastography and dynamic contrast-enhanced MR in benign and malignant breast masses.American journal of translational research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The surrounding tissue of lesions located in the mammary fat layer is mainly fat, not mammary glands. Are the currently used Breast Imaging Reporting and Data System (BI-RADS) classifications and ultrasound elasticity appropriate for such lesions? In the present study, we discuss the value of elastography and BI-RADS classification in the evaluation of masses in the superficial fat layer of the breast. Methods: Seventy-five breast masses within the fat layer that met inclusion criteria were included in the study. Using histopathology as the gold standard, we retrospectively analyzed whether the ultrasound elastography and BI-RADS classification results were consistent with the pathological results. Results: Histological analysis showed that 73 tumors were benign and 2 were malignant. According to the BI-RADS classification and treatment principle, 60% (45/75) of the masses were classified into category 4 and require breast biopsy. But only 4.4% (2/45) of these masses were malignant, and 95.6% (43/45) were overtreated. If we consider the masses with well-defined margins and within the fat layer on the surface of the breast glands as likely benign (BI-RADS category 3), the probability of malignancy is 1.4%. This is consistent with the BI-RADS classification probability of malignancy. According to this BI-RADS classification, only 1.3% (1/75) of patients required biopsy. Conclusions: The findings of this study suggest that breast masses located in the fat layer are prone to be classified into category 4 by BI-RADS and thus be subjected to unnecessary biopsies. Ultrasound elastography can easily misdiagnose benign masses as malignant. It is suggested that ultrasound elastography can downgrade the BI-RADS classification, but not upgrade it. It is more reasonable for these breast masses to be classified as BI-RADS 3 for follow-up observation when the boundary is clear.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.